PulmoCare-L 50 mcg/puff Inhaler Uses, Dosage, Side Effects and more

Uses

PulmoCare-L 50 mcg/puff Inhaler tablet is used for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution or Inhaler is used for the treatment or prevention of bronchospasm in adults, adolescents, and children with reversible obstructive airway disease.

PulmoCare-L 50 mcg/puff Inhaler is also used to associated treatment for these conditions: Bronchospasm

How PulmoCare-L 50 mcg/puff Inhaler works

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Dosage

PulmoCare-L 50 mcg/puff Inhaler dosage

PulmoCare-L 50 mcg/puff Inhaler Tablet-

• Adults and children above 12 years: 1-2 mg three times daily.
• Children (6 -11 years): 1 mg three times daily.

Syrup-

• Adults and children above 12 years: 5-10 ml three times daily.
• Children (6 -11 years): 5 ml three times daily.

PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution-

This Nebuliser Solutionis supplied in unit-dose ampoules and requires no dilution before administration by nebulization.

• Children (6 months-11 years): The recommended dosage is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day.
• Adults and Adolescents above 12 years old: The recommended starting dosage is 0.63 mg administered three to four times a day, every 6 to 8 hours, by nebulization.
• Patients 12 years of age and older with more severe asthma or patients who do not respond adequately: 0.63 mg of PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution may benefit from a dosage of 1.25 mg three times a day.

PulmoCare-L 50 mcg/puff Inhaler Inhaler-

You should take your PulmoCare-L 50 mcg/puff Inhaler Inhaler as needed for an asthma attack at any time of day, with or without food, by taking 1-2 puffs up to 4 times daily and no more than 8 puffs in 24 hours. If you are using your PulmoCare-L 50 mcg/puff Inhaler Inhaler more than 3-4 times a week this may indicate that your asthma is not well controlled and you may need to review your medication. You can also use your PulmoCare-L 50 mcg/puff Inhaler Inhaler to prevent allergy or exercise induced asthma by taking 2 puffs 15 minutes before exercise or exposure to a known allergen.

Side Effects

Potentially serious side effects like hypokalamia may result from ß-2 agonist therapy. This effect may be potentiated by hypoxia. The other likely side effects are gastrointestinal disturbances such as nausea, vomiting, burning substernal or epigastric pain and diarrhoea. In some cases nervousness, headache, dizziness, fatigue and sleeplessness may occur.

Precaution

Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. Oral PulmoCare-L 50 mcg/puff Inhaler should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias or hypertension. PulmoCare-L 50 mcg/puff Inhaler can be used with caution after myocardial infarction.

PulmoCare-L 50 mcg/puff Inhaler Hydrochloride, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, hypertension, and cardiac arrhythmias; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution or Inhaler must not be injected.

Interaction

Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with PulmoCare-L 50 mcg/puff Inhaler. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

Food Interaction

Elimination Route

Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.

Half Life

3.3 - 4 hours

Elimination Route

excreted into the urine.

Pregnancy & Breastfeeding use

Use in pregnancy: Use of oral PulmoCare-L 50 mcg/puff Inhaler in pregnant women should be considered only if the expected benefit to the mother is greater than any possible risk to the foetus or the infant.

Use in lactation: It is not known whether PulmoCare-L 50 mcg/puff Inhaler is excreted in human milk. Caution should be exercised when oral PulmoCare-L 50 mcg/puff Inhaler is administered to a nursing woman.

Pregnancy: There are no adequate and well-controlled studies of PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution in pregnant women. PulmoCare-L 50 mcg/puff Inhaler Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: It is not known whether PulmoCare-L 50 mcg/puff Inhaler is excreted in human milk. Caution should be exercised when PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution is administered to a nursing woman.

Contraindication

PulmoCare-L 50 mcg/puff Inhaler Nebuliser Solution is contraindicated in patients with a history of hypersensitivity to PulmoCare-L 50 mcg/puff Inhaler Hydrochloride or racemic salbutamol.

Acute Overdose

The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under side effects e.g., tachycardia, nervousness, headache, tremor, nausea, dizziness, fatigue and sleeplessness. Hypokalaemia also may occur. Treatment consists of discontinuation of oral PulmoCare-L 50 mcg/puff Inhaler together with appropriate symptomatic therapy. In the event of serious poisoning, the stomach should be emptied and, if necessary, a beta-blocker administered with caution in patients with a history of bronchospasm.

Storage Condition

Store at cool and dry place. Protected from light and moisture. Keep out of the reach of children.

Innovators Monograph